Orphazyme AS (CHIX:ORPHAC) Debt-to-Asset : 0.00 (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Debt-to-Asset?

Orphazyme AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was kr0.00 Mil. Orphazyme AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was kr0.00 Mil. Orphazyme AS's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2022 was kr93.59 Mil. Orphazyme AS's debt to asset for the quarter that ended in Jun. 2022 was 0.00.

Orphazyme AS Debt-to-Asset Historical Data

The historical data trend for Orphazyme AS's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Debt-to-Asset Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Asset

Get a 7-Day Free Trial

0.43

0.09

0.23

Orphazyme AS Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Debt-to-Asset	Get a 7-Day Free Trial									0.12	0.09	0.14	0.23	-

Competitive Comparison of Orphazyme AS's Debt-to-Asset

For the Biotechnology subindustry, Orphazyme AS's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orphazyme AS's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's Debt-to-Asset falls into.

Orphazyme AS Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Orphazyme AS's Debt-to-Asset for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(33.561	+	6.407)	/	173.229
	=	0.23

Orphazyme AS's Debt-to-Asset for the quarter that ended in Jun. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	93.589
	=	0.00

Orphazyme AS (CHIX:ORPHAc) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Orphazyme AS Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS Headlines

No Headlines